Overactive bladder/enuresis:
Indications for VESICARE:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Adult Dosage:
Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: max 5mg once daily.
Children Dosage:
Not established.
VESICARE Contraindications:
For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.
VESICARE Warnings/Precautions:
Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.
See Also:
VESICARE Classification:
Muscarinic antagonist.
VESICARE Interactions:
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.
Adverse Reactions:
Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90; Susp—150mL
